Advancing subcutaneous infusion therapy for patients through innovation and partnerships

More than one million people around the world rely on Convatec infusion sets every day. 

The latest edition of ONdrugDelivery Journal, a widely respected journal focused on drug delivery innovation, features our leading innovation in subcutaneous infusion therapy with our Neria™ Guard infusion set – a lifeline for those with chronic conditions such as diabetes and advanced Parkinson’s disease.

The editorial was co-authored by Julien Vandewalle, VP, Commercial & Strategy, Infusion Care, and Clare Holden, VP, R&D, Infusion Care and recognises how Convatec’s innovation and strategic partnerships with pharmaceutical and medical device companies are improving people’s lives – from our commitment to patient-centric design and sustainability, coupled with significant research and development (R&D) investment and manufacturing excellence. 

Read the feature in the latest edition of ONdrugDelivery to learn more.

Contact
Media: MediaRelations@convatec.com
Investor Relations: ir@convatec.com

About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec’s revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com